AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Increased by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. grew its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 3.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 91,978 shares of the company’s stock after buying an additional 3,359 shares during the period. Oppenheimer Asset Management Inc.’s holdings in AstraZeneca were worth $7,166,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its position in shares of AstraZeneca by 17.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after buying an additional 9,002,450 shares during the last quarter. Swedbank AB bought a new position in AstraZeneca in the first quarter worth about $186,127,000. Manning & Napier Advisors LLC acquired a new position in AstraZeneca in the second quarter valued at approximately $188,476,000. Hsbc Holdings PLC grew its holdings in shares of AstraZeneca by 750.3% during the second quarter. Hsbc Holdings PLC now owns 1,283,274 shares of the company’s stock valued at $100,523,000 after purchasing an additional 1,132,362 shares during the last quarter. Finally, Farallon Capital Management LLC raised its position in shares of AstraZeneca by 65.1% during the 2nd quarter. Farallon Capital Management LLC now owns 2,409,718 shares of the company’s stock worth $187,934,000 after purchasing an additional 950,000 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

AZN has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. Finally, TD Cowen upped their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Trading Down 0.4 %

Shares of AZN stock opened at $65.04 on Friday. The firm has a market capitalization of $201.66 billion, a PE ratio of 31.12, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 0.93. AstraZeneca PLC has a 1 year low of $60.47 and a 1 year high of $87.68. The stock has a fifty day moving average of $75.79 and a two-hundred day moving average of $78.38.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The company’s quarterly revenue was up 18.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.87 earnings per share. As a group, research analysts expect that AstraZeneca PLC will post 4.07 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.